Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.
Samuel Hsiang LimBeatriz GrosEsha SharmaAnouk LehmannJames O LindsayLouise CaulfieldDaniel R GayaJo TaylorJimmy LimdiJon KwokElinor ShuttleworthAnjan DharGemma BurdgeChristian SelingerSara CococciaCharles MurrayKarthiha BalendranTim RaineBecky GeorgeGareth WalkerRobin AldridgePeter M IrvingCharlie W LeesMark SamaanPublished in: Inflammatory bowel diseases (2023)
Switching to SC vedolizumab appears as effective, safe, and well tolerated as continued IV treatment and maintains comparable disease control and quality of life as IV treatment at 52 weeks.